ADC Therapeutics ADCT
NYSE ADCT
$1.22 -0.08 (-6.15%)
As of: Sep 9, 2026 · 3:59 PM EDT

ADC Therapeutics (ADCT) Restructuring Costs (2025 - 2026)

ADC Therapeutics' (ADCT) quarterly Restructuring Costs came in at $2.7 million in Q2 2026, down 79.57% year-over-year from $13.1 million in Q2 2025, and up 609.28% quarter-over-quarter from $377000.0 in Q3 2025.

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo
Analysis

ADC Therapeutics (ADCT) Restructuring Costs (2025 - 2026) Analysis & Trends

ADC Therapeutics has disclosed Restructuring Costs across 2 years of filings, most recently posting $2.7 million for Q2 2026.

Peer Set

Peer Comparison

All peers
# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn
10 ADC Therapeutics 172.04 Mn -47.07 Mn 17.14 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 2.67 Mn
Sep 30, 2025 377,000.00
Jun 30, 2025 13.09 Mn